Results 31 to 40 of about 89,060 (300)

Prognostic significance of p16 immunohistochemical expression in urothelial carcinoma

open access: yesSurgical and Experimental Pathology, 2019
Background p16 is the protein product of most commonly involved gene in bladder carcinogenesis. Therefore, we performed an immunohistochemical study to evaluate association of p16 overexpression with prognostic parameters in bladder cancer.
Atif Ali Hashmi   +5 more
doaj   +1 more source

P16 Cutoff in Head and Neck Squamous Cell Carcinoma: Correlation between Tumor and Patient Characteristics and Outcome

open access: yesThe International Journal of Biological Markers, 2016
Background p16 has been indicated as a suitable surrogate biomarker of HPV infection. The prognosis of p16-positive oropharynx tumors (OTs) of squamous cell carcinoma (SCC) histology is better than that of p16-negative tumors.
Marco Carlo Merlano   +7 more
doaj   +1 more source

p16 Stimulates CDC42-dependent migration of hepatocellular carcinoma cells. [PDF]

open access: yesPLoS ONE, 2013
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Tumor dissemination to the extra-hepatic region of the portal vein, lymph nodes, lungs or bones contributes to the high mortality seen in HCC; yet, the molecular ...
Ya-Wen Chen   +6 more
doaj   +1 more source

Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth. [PDF]

open access: yesPLoS ONE, 2014
The INK4A locus codes for two independent tumor suppressors, p14ARF and p16/CDKN2A, and is frequently mutated in many cancers. Here we report a novel deletion/substitution from CC to T in the shared exon 2 of p14ARF/p16 in a melanoma cell line.
Richard T Williams   +6 more
doaj   +1 more source

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib.

open access: yesPLoS ONE, 2019
The P16 (CDKN2Aink4a) gene is an endogenous CDK4/6 inhibitor. Palbociclib (PD0332991) is an anti-CDK4/6 chemical for cancer treatment. P16 is most frequently inactivated by copy number deletion and DNA methylation in cancers. It is well known that cancer
Paiyun Li   +4 more
doaj   +1 more source

p16, pRb, and p53 in Feline Oral Squamous Cell Carcinoma

open access: yesVeterinary Sciences, 2016
Feline oral squamous cell carcinoma (FOSCC) is a highly aggressive head and neck cancer in cats, but the molecular pathogenesis of this cancer is still uncertain.
Wachiraphan Supsavhad   +3 more
doaj   +1 more source

Molecular profiling and survival outcomes of p16+ compared to p16- oropharynx squamous cell cancer patients

open access: yes, 2021
e18026 Background: Previous studies have consistently shown that p16+ oropharynx squamous cell cancer (OPSCC) patients have better outcomes. The significance of molecular and transcriptional signatures and its correlation with p16 expression remains ...
Hughes, Brittany Nicole   +11 more
core   +1 more source

TNM 8 staging system beyond p16:Double HPV/p16 status is superior to p16 alone in predicting outcome in oropharyngeal squamous cell carcinoma [PDF]

open access: yes
PURPOSE: The assessment of p16INK4a (p16) in oropharyngeal squamous cell carcinoma (OPSCC) has been incorporated into tumor classification, as p16 has been shown to impact survival probability.
von Buchwald, Christian,   +78 more
core   +5 more sources

Digital Spatial Profiling identifies distinct patterns of immuno-oncology-related gene expression within oropharyngeal tumours in relation to HPV and p16 status

open access: yesFrontiers in Oncology
BackgroundThe incidence of oropharyngeal cancer (OPC) is increasing, due mainly to a rise in Human Papilloma Virus (HPV)-mediated disease. HPV-mediated OPC has significantly better prognosis compared with HPV-negative OPC, stimulating interest in ...
Jill M. Brooks   +8 more
doaj   +1 more source

The hypermethylation of p16 gene exon 1 and exon 2: potential biomarkers for colorectal cancer and are associated with cancer pathological staging

open access: yesBMC Cancer, 2018
Background Tumor suppressor gene p16 promoter hypermethylation has been widely studied in colorectal cancer (CRC), yet its clinicopathological significance remains controversial.
Xiaoxia Ye   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy